Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization
开发用于中和 SARS-CoV-2 的多价、超强纳米抗体混合物
基本信息
- 批准号:10444442
- 负责人:
- 金额:$ 76.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-09 至 2022-02-18
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAerosolsAffinityAftercareAntibodiesBindingBiological AvailabilityBiomedical EngineeringCOVID-19COVID-19 outbreakCOVID-19 therapeuticsCOVID-19 treatmentCellsClinicalClinical ResearchClinical TrialsCommunitiesComputer softwareCoronavirusDepositionDevelopmentDiagnostic ReagentDoseDrug StorageEpitope MappingEpitopesEventFutureGenotypeGoalsHamstersHumanImmunoglobulin FragmentsImmunoglobulin GInfectionInhalationInnovative TherapyLungMicrobeModelingMutationNebulizerPharmaceutical PreparationsPrimatesProductionPropertyProteomicsPulmonary PathologyReportingResearchResistanceResolutionRespiratory SystemSARS-CoV-2 infectionSARS-CoV-2 variantScienceStructureSystemTechnologyTherapeuticTherapeutic AgentsTranslationsViralViral AntibodiesViral Load resultViral PneumoniaVirusaerosolizedbaseclinical applicationcostcost effectivedesigndrug developmentdrug qualityefficacy evaluationemerging pathogenflexibilityglobal healthimprovedin vivoinsightinterdisciplinary approachinterestmultidisciplinarynanobodiesnovelnovel therapeuticsnovel vaccinespandemic diseasepathogenpreclinical efficacypreclinical evaluationpreventprotein foldingrational designreceptor bindingrespiratory virusstructural biologytherapeutic candidatetherapeutically effectivetranslational potentialvariants of concern
项目摘要
PROJECT SUMMARY/ABSTRACT
The outbreak of COVID-19 has severely impacted global health and the economy. Cost-effective, highly
efficacious therapeutics are urgently needed. Camelid VHH antibodies or nanobodies (Nbs) are small, highly
stable, easily bioengineered, and can be rapidly and economically manufactured from microbes. They are
highly robust and are flexible for administration, including possible delivery by nebulization. Together these
unique properties of Nbs make their uses against respiratory viruses such as SARS-CoV-2 especially
appealing.
We recently developed a disruptive proteomic technology for large-scale identification of multi-epitope, drug-
quality Nbs (Xiang et. al, Cell Systems. 2021). Using this technology, we identified > 8,000 high-affinity Nbs for
the SARS-CoV-2 spike (S) receptor-binding domain (RBD) including Nbs that target highly neutralizing
epitopes with sub-pM affinities and can neutralize SARS-CoV-2 at sub-ng/ml concentrations, which are
unprecedented for antiviral antibody fragments. Structural proteomics revealed multiple distinct epitopes and
potential neutralization mechanisms. Bioengineering of multi-epitope and multivalent constructs improved the
potency to below 0.1 ng/ml (Xiang, et. al, Science. 2020). Most recently, we have demonstrated the high
preclinical efficacy of an ultrapotent and stable trimeric Nb construct (PiN-21) for inhalation treatment of SARS-
CoV-2 infection in a sensitive COVID-19 model (Nambulli, et. al, Science Advances. 2021). Intranasal delivery
of PiN-21 at 0.6 mg/kg substantially reduces viral burdens in both airways. Critically, aerosol delivery of PiN-21
at 0.2 mg/kg decreases lung viral titers by 6-logs, minimizing lung pathology post-infection and preventing viral
pneumonia. Combined with the marked stability and low production cost, this innovative therapy may provide a
convenient and cost-effective option to mitigate the evolving pandemic and future events.
In the revision, we aim to identify and characterize highly potent Nbs that are highly resistant to the variants of
concern (VOCs) of SARS-CoV-2, investigate the neutralization mechanisms by structural approaches, and
develop ultrapotent Nb constructs into safe and effective therapeutics. Our central hypothesis is that Nbs can
be bioengineered into multivalent and ultrapotent forms to resist the mutational escape and the variants of
concerns (VOCs) of SARS-CoV-2.
Completion of our proposed studies will lead to cost-effective and convenient COVID-19 therapeutic
candidates for translation into clinical trials. High-resolution structural studies will provide critical insights into
how Nbs uniquely target the virus for high-affinity binding and neutralization. Critically, this project will serve as
the testbed of our multidisciplinary platform to develop potent therapeutic and diagnostic reagents for future
pandemics caused by coronaviruses or other pathogens.
项目总结/摘要
COVID-19的爆发严重影响了全球健康和经济。成本效益高,
迫切需要有效的治疗方法。骆驼科VHH抗体或纳米抗体(Nbs)是小的、高度特异性的,
稳定,易于生物工程化,并且可以快速和经济地从微生物制造。他们是
高度稳健并且对于给药是灵活的,包括可能通过雾化递送。综合这些
Nbs的独特性质使其可用于对抗呼吸道病毒,特别是SARS-CoV-2,
很吸引人。
我们最近开发了一种破坏性的蛋白质组学技术,用于大规模鉴定多表位,药物,
质量Nbs(Xiang et.等人,Cell Systems. 2021年)。使用这项技术,我们鉴定了> 8,000个高亲和力Nbs,
SARS-CoV-2刺突(S)受体结合结构域(RBD),包括靶向高度中和
表位具有亚pM亲和力,可以中和浓度低于ng/ml的SARS-CoV-2,
前所未有的抗病毒抗体片段。结构蛋白质组学揭示了多个不同的表位,
潜在的中和机制。多表位和多价构建体的生物工程改善了
lng/ml(Xiang,et. al,科学。2020年)。最近,我们展示了
吸入治疗SARS的超有效和稳定的三聚体Nb构建体(PiN-21)的临床前功效-
在敏感的COVID-19模型中的CoV-2感染(Nambulli,et.《科学进展》2021年)。鼻内递送
0.6mg/kg的PiN-21显著降低了两个气道中的病毒负荷。关键是,PiN-21的气雾剂递送
在0.2 mg/kg时,肺病毒滴度降低6-log,最大限度地减少感染后肺病理学,并预防病毒感染。
肺炎结合显著的稳定性和低生产成本,这种创新疗法可能提供一种
方便和具有成本效益的选择,以减轻不断演变的流行病和未来的事件。
在修订版中,我们的目标是识别和表征对以下变体具有高度抗性的高效Nbs:
关注(VOCs)的SARS-CoV-2,研究中和机制的结构方法,
将超强效Nb构建体开发成安全有效的治疗剂。我们的中心假设是Nbs可以
被生物工程改造成多价和超有效的形式,以抵抗突变逃逸和
SARS-CoV-2的VOC。
完成我们提议的研究将带来具有成本效益且方便的COVID-19治疗方法
用于临床试验的候选人。高分辨率的结构研究将提供关键的见解,
Nbs如何独特地靶向病毒以进行高亲和力结合和中和。关键是,该项目将作为
我们的多学科平台的测试平台,以开发未来有效的治疗和诊断试剂
由冠状病毒或其他病原体引起的流行病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Paul Duprex其他文献
William Paul Duprex的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Paul Duprex', 18)}}的其他基金
Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
升级匹兹堡大学疫苗研究中心区域生物防护实验室的行政补充
- 批准号:
10631339 - 财政年份:2022
- 资助金额:
$ 76.9万 - 项目类别:
Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
升级疫苗研究中心内的匹兹堡大学区域生物防护实验室
- 批准号:
10394474 - 财政年份:2021
- 资助金额:
$ 76.9万 - 项目类别:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
转变疫苗安全范式:从经验衰减到理性衰减
- 批准号:
8664340 - 财政年份:2013
- 资助金额:
$ 76.9万 - 项目类别:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
转变疫苗安全范式:从经验衰减到理性衰减
- 批准号:
8504483 - 财政年份:2013
- 资助金额:
$ 76.9万 - 项目类别:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
转变疫苗安全范式:从经验衰减到理性衰减
- 批准号:
9064740 - 财政年份:2013
- 资助金额:
$ 76.9万 - 项目类别:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
转变疫苗安全范式:从经验衰减到理性衰减
- 批准号:
8852530 - 财政年份:2013
- 资助金额:
$ 76.9万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 76.9万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 76.9万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 76.9万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 76.9万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 76.9万 - 项目类别:
Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 76.9万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 76.9万 - 项目类别:
Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 76.9万 - 项目类别:
Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 76.9万 - 项目类别:
Small Business Research Initiative